Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin

Leuk Res. 2010 Jul;34(7):e152-3. doi: 10.1016/j.leukres.2009.12.006. Epub 2010 Jan 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / genetics
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Gemtuzumab
  • Humans
  • Idarubicin / administration & dosage
  • Immunotoxins / therapeutic use*
  • Leukemia, Monocytic, Acute / blood
  • Leukemia, Monocytic, Acute / drug therapy*
  • Leukemia, Monocytic, Acute / genetics
  • Male
  • Myeloid-Lymphoid Leukemia Protein / blood*
  • Myeloid-Lymphoid Leukemia Protein / genetics
  • Neoplasm, Residual / drug therapy
  • Oncogene Proteins, Fusion / blood*
  • Oncogene Proteins, Fusion / genetics
  • Remission Induction

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Immunotoxins
  • MLL-AF9 fusion protein, human
  • Oncogene Proteins, Fusion
  • Cytarabine
  • Myeloid-Lymphoid Leukemia Protein
  • Gemtuzumab
  • Idarubicin
  • Daunorubicin